Financial Performance - The company's operating revenue for Q3 2022 was CNY 374,316,058.66, representing a year-on-year increase of 28.20%[3] - The net profit attributable to shareholders for Q3 2022 was CNY 55,188,163.08, reflecting a significant increase of 56.69% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was CNY 51,489,672.76, up by 50.48% year-on-year[3] - The net profit attributable to shareholders for the year-to-date period was CNY 137,503,187.70, marking a 68.18% increase year-on-year[3] - Net profit for the first three quarters of 2022 was ¥146,550,717.75, representing a 65.7% increase from ¥88,422,616.59 in 2021[19] Earnings and Shareholder Returns - The basic earnings per share for Q3 2022 was CNY 0.19, an increase of 35.71% compared to the same period last year[4] - The diluted earnings per share for Q3 2022 was also CNY 0.19, reflecting a 35.71% increase year-on-year[4] - Earnings per share for the third quarter of 2022 were ¥0.47, compared to ¥0.31 in the same quarter of the previous year[19] Cash Flow and Liquidity - The cash flow from operating activities for the year-to-date period reached CNY 262,058,709.96, showing a remarkable increase of 173.83%[3] - Operating cash inflow for the first three quarters of 2022 reached ¥1,157,197,010.56, a 36% increase from ¥850,485,045.77 in the same period of 2021[21] - Net cash flow from operating activities was ¥262,058,709.96, compared to ¥95,699,591.38 in the previous year, marking a significant increase[22] - The ending balance of cash and cash equivalents was ¥237,454,061.16, up from ¥152,120,160.68 in the same period last year[23] - The company reported cash and cash equivalents of ¥237,454,061.16 as of September 30, 2022, down from ¥604,584,094.35 at the end of 2021[12] Assets and Liabilities - The total assets at the end of Q3 2022 amounted to CNY 2,271,288,230.53, representing a growth of 6.52% from the end of the previous year[4] - The total assets as of the end of the third quarter of 2022 amounted to ¥2,271,288,230.53, an increase from ¥2,132,362,965.18 at the end of the previous year[14] - Total liabilities increased to ¥581,157,103.76 from ¥540,870,556.73 year-over-year[14] - The total current assets amount to ¥948,536,357.80, compared to ¥974,541,894.66 at the end of 2021[12] Investments and Expenditures - The company reported an investment income of ¥5,510,407.22, a significant increase from ¥431,062.62 in the previous year[18] - Research and development expenses for the first three quarters of 2022 were ¥52,910,456.51, up 58.8% from ¥33,314,053.73 in the same period of 2021[18] - Total cash outflow for investment activities was ¥1,459,394,041.89, compared to ¥270,181,566.86 in the previous year, indicating increased investment spending[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,535[10] - The largest shareholder, Gaobo Investment (Hong Kong) Limited, holds 92,019,200 shares, representing 31.36% of total shares, with 31,200,000 shares pledged[10] - Guangzhou Songwei Enterprise Management Consulting Co., Ltd. holds 44,864,856 shares, accounting for 15.29% of total shares, with 14,800,000 shares pledged[10] Other Notable Information - The company has not disclosed any significant new product developments or market expansion strategies in the current report[11] - There are no significant changes in the shareholder structure or related party transactions reported[11]
维力医疗(603309) - 2022 Q3 - 季度财报